Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lexaria Bioscience (LEXX) Income from Continuing Operations (2017 - 2025)

Lexaria Bioscience's Income from Continuing Operations history spans 9 years, with the latest figure at 1575410.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 41.45% year-over-year to 1575410.0; the TTM value through Nov 2025 reached 10762434.0, down 47.48%, while the annual FY2025 figure was 11877720.0, 106.97% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 1575410.0 at Lexaria Bioscience, up from 2685781.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 668006.0 in Q1 2024 and bottomed at 3750231.0 in Q2 2025.
  • The 5-year median for Income from Continuing Operations is 1719169.0 (2022), against an average of 1865937.1.
  • The largest annual shift saw Income from Continuing Operations crashed 2039.29% in 2021 before it soared 49.53% in 2024.
  • A 5-year view of Income from Continuing Operations shows it stood at 2003482.0 in 2021, then rose by 15.38% to 1695419.0 in 2022, then skyrocketed by 33.24% to 1131823.0 in 2023, then plummeted by 137.73% to 2690696.0 in 2024, then surged by 41.45% to 1575410.0 in 2025.
  • Per Business Quant, the three most recent readings for LEXX's Income from Continuing Operations are 1575410.0 (Q4 2025), 2685781.0 (Q3 2025), and 3750231.0 (Q2 2025).